Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.

[1]  Z. Obermeyer,et al.  Predicting the Future - Big Data, Machine Learning, and Clinical Medicine. , 2016, The New England journal of medicine.

[2]  A. Loewenstein,et al.  Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration. , 2016, Ophthalmology.

[3]  Glenn J Jaffe,et al.  Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. , 2016, Ophthalmology.

[4]  Michael Pircher,et al.  Automated Identification and Quantification of Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration Using Polarization-Sensitive OCT. , 2016, Investigative ophthalmology & visual science.

[5]  Bianca S. Gerendas,et al.  Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. , 2016, JAMA ophthalmology.

[6]  U. Schmidt-Erfurth,et al.  A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration , 2016, Progress in Retinal and Eye Research.

[7]  Glenn J Jaffe,et al.  Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2016, Ophthalmology.

[8]  Jiayan Huang,et al.  Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). , 2015, Ophthalmology.

[9]  Philippe Burlina,et al.  Automated segmentation of geographic atrophy of the retinal epithelium via random forests in AREDS color fundus images , 2015, Comput. Biol. Medicine.

[10]  Georg Langs,et al.  Spatio-Temporal Signatures to Predict Retinal Disease Recurrence , 2015, IPMI.

[11]  Georg Langs,et al.  Predicting Semantic Descriptions from Medical Images with Convolutional Neural Networks , 2015, IPMI.

[12]  Georg Langs,et al.  Motion Artefact Correction in Retinal Optical Coherence Tomography Using Local Symmetry , 2014, MICCAI.

[13]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[14]  Danielle B. Gutierrez,et al.  Quantitative autofluorescence and cell density maps of the human retinal pigment epithelium. , 2014, Investigative ophthalmology & visual science.

[15]  U Chakravarthy,et al.  The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. , 2014, Ophthalmology.

[16]  Amitha Domalpally,et al.  Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. , 2014, Ophthalmology.

[17]  R. Avery,et al.  Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[18]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[19]  Allen C Ho,et al.  Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.

[20]  S. Sivaprasad,et al.  Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. , 2013, American journal of ophthalmology.

[21]  M. Larsen,et al.  Predictors of 1‐year visual outcome in neovascular age‐related macular degeneration following intravitreal ranibizumab treatment , 2013, Acta ophthalmologica.

[22]  Correlation of OCT characteristics and retinal sensitivity in neovascular age-related macular degeneration in the course of monthly ranibizumab treatment. , 2013, Investigative ophthalmology & visual science.

[23]  U. Schmidt-Erfurth,et al.  Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. , 2012, Investigative ophthalmology & visual science.

[24]  TIME TO FIRST TREATMENT: The Significance of Early Treatment of Exudative Age-related Macular Degeneration , 2012, Retina.

[25]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[26]  Xiaodong Wu,et al.  Automated 3-D Intraretinal Layer Segmentation of Macular Spectral-Domain Optical Coherence Tomography Images , 2009, IEEE Transactions on Medical Imaging.

[27]  J. Vander,et al.  Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .

[28]  P. Kaiser,et al.  Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. , 2007, American journal of ophthalmology.

[29]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[30]  R. Bhisitkul,et al.  Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.

[31]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[32]  Sanjay Sharma,et al.  Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. , 2005, Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie.

[33]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.